MorphoSys AG buy Saftman
Start price
12.09.23
/
50%
€29.49
Target price
12.09.24
-
Performance (%)
35.54%
End price
31.01.24
€39.97
Summary
This prediction ended on 31.01.24 with a price of €39.97. The BUY prediction by Saftman for MorphoSys AG saw massive gains of 35.54%. Saftman has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| MorphoSys AG | 0.148% | 0.148% |
| iShares Core DAX® | 2.594% | -1.861% |
| iShares Nasdaq 100 | 3.553% | -2.064% |
| iShares Nikkei 225® | 0.687% | -8.704% |
| iShares S&P 500 | 2.209% | -1.988% |
Comments by Saftman for this prediction
In the thread Morphosys AG diskutieren
Saftman hat das Wertpapier MorphoSys AG in seinem Wikifolio Trendfolge nach Levy gekauft.